Hormone therapy in oophorectomized BRCA1/2 mutation carriers

Menopause

Volumn 21, Issue 7, 2014, Pages 763-768

  Marchetti, Claudia ^a   Iadarola, Roberta ^a   Palaia, Innocenza ^a   Di Donato, Violante ^a   Perniola, Giorgia ^a   Muzii, Ludovico ^a   Panici, Perluigi Bendetti ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BRCA; Hormone therapy; Menopause; Ovarian cancer; Prophylactic oophorectomy; Quality of life

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

CARDIOVASCULAR RISK; FEMALE; GENE MUTATION; HETEROZYGOTE; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; MENOPAUSE; OVARIECTOMY; QUALITY OF LIFE; REVIEW; SALPINGOOOPHORECTOMY; SEXUALITY; BREAST NEOPLASMS; ESTROGEN THERAPY; FALLOPIAN TUBE NEOPLASMS; HOT FLASHES; OVARIAN NEOPLASMS; POSTOPERATIVE CARE; PROCEDURES; SALPINGOSTOMY; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HOT FLASHES; HUMANS; OVARIAN NEOPLASMS; OVARIECTOMY; POSTOPERATIVE CARE; SALPINGOSTOMY;

EID: 84903165369     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000126     Document Type: Review

References (58)

1. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004;95:866-871. (Pubitemid 40045520)
2. Kurian AW, McClure LA, John E, et al. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 2009;101:1058-1065.
3. Nanda R, Schumm LP, Cummings S, et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 2005;294:1925-1933. (Pubitemid 41464694)
4. Bougie O, Weberpals JI. Clinical considerations of BRCA1-and BRCA2-mutation carriers: a review. Int J Surg Oncol 2011;2011:374012.
5. King MC, Marks JH, Mandell JB. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-646. (Pubitemid 37310920)
6. Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1973-2009), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch [released April 2012 based on November 2011 submission]. Available at: www.seer.cancer.gov.
7. Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol 2003;88:S8-S10, discussion S11-S13.
8. Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;5:1117-1130. (Pubitemid 36530000)
9. Satagopan JM, Boyd J, Kauff ND, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002;8:3776-3781. (Pubitemid 35424769)
10. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-2318. (Pubitemid 34441658)
11. Foulkes WD, Kelly Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1-and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004;10:2029-2034. (Pubitemid 38375563)
12. Gaarenstroom KN, van der Hiel B, Tollenaar RA, et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 2006;16:54-59.
13. Oei AL, Massuger LF, Bulten J, et al. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 2006;94:814-819.
14. Olivier RI, Lubsen-Brandsma MA, Verhoef S, et al. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006;100:20-26. (Pubitemid 41815044)
15. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-1615. (Pubitemid 34755668)
16. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622. (Pubitemid 34755669)
17. Gadducci A, Biglia N, Cosio S, et al. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. Gynecol Endocrinol 2010;26:568-577.
18. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol 2007;25:2921-2927. (Pubitemid 47123156)
19. Metcalfe KA, Ghadirian P, Rosen B, et al. Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Med 2007;2:92-98.
20. Finch A, Evans G, Narod SA. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health 2012;5:543-555.
21. Kauff N, Domchek S, Friebel T, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multi-center, prospective study. J Clin Oncol 2008;26:1331-1337.
22. Rebbeck T, Kauff N, Domchek S. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA 2 mutation carriers. J Natl Cancer Inst 2009;101:80-87.
23. SLgaard M, Kjaer SK, Gayther S. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. Acta Obstet Gynecol Scand 2006;85:93-105. (Pubitemid 43879130)
24. Sigal BM, Munoz DF, Kurian AW, et al. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012;21:1066-1077.
25. American College of Obstetrics and Gynecology. ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy. Obstet Gynecol 2008;111:231-241.
26. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines. Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1. Fort Washington, PA: National Comprehensive Cancer Network, 2010.
27. Alvarado-Cabrero I, Young RH, Vamvakas EC, et al. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 1999;72:367-379. (Pubitemid 29118195)
28. Beiner ME, Finch A, Rosen B, et al. Hereditary Ovarian Cancer Clinical Study Group. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 2007;104:7-10. (Pubitemid 46054134)
29. Hornreich G, Beller U, Lavie O, et al. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol 1999;75:300-304. (Pubitemid 29523039)
30. Lavie O, Ben-Arie A, Pilip A, et al. BRCA2 germline mutation in a woman with uterine serous papillary carcinomaVcase report. Gynecol Oncol 2005;99:486-488. (Pubitemid 41502865)
31. Biron-Shental T, Drucker L, Altaras M, et al. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur J Surg Oncol 2006;32:1097-1100. (Pubitemid 44774386)
32. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008;122:2017-2022. (Pubitemid 351441190)
33. Madalinska JB, Hollenstein J, Bleiker E, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005; 23:6890-6898.
34. Rocca WA, Grossardt BR, de Andrade M, et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006;7:821-828. (Pubitemid 44464065)
35. Judd HL. Hormonal dynamics associated with the menopause. Clin Obstet Gynecol 1976;19:775-788. (Pubitemid 8007370)
36. Sluijmer AV, Heineman MJ, De Jong FH, et al. Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy. J Clin Endocrinol Metab 1995;80:2163-2167.
37. Finch A, Metcalfe KA, Chiang JK, et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 2011;121:163-168.
38. Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110. (Pubitemid 17052498)
39. Finch A, Narod SA. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review. Maturitas 2011;70:261-265.
40. Atsma F, Bartelink ML, Grobbee DE, et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265-279.
41. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006;7:223-229. (Pubitemid 43286452)
42. Domchek S, Friebel T, Singer C. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-975.
43. Biglia N, Torta R, Roagna R, et al. Evaluation of low dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas 2005;52:78-85. (Pubitemid 41242746)
44. Loibl S, Schwedler K, von Minckwitz G, et al. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patientsVa doubleblind, randomized study. Ann Oncol 2007;18:689-693. (Pubitemid 46523272)
45. Buijs C, Mom CH, Willemse PH, et al. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 2009;115:573-580.
46. Bedell S, Nachtigall M, Naftolin F. The pros and cons of plant estrogens for menopause. J Steroid Biochem Mol Biol 2012;12:256-257.
47. Nathorst-Böös J, von Schoultz B, Carlström K. Elective ovarian removal and estrogen replacement therapyVeffects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol 1993;14:283-293. (Pubitemid 24016900)
48. Meiser B, Tiller K, Gleeson MA, et al. Psychological impact of prophylactic oophorectomy in women at increased risk for ovarian cancer. Psychooncology 2000;9:496-503. (Pubitemid 32010922)
49. Elit L, Esplen MJ, Butler K, Narod S. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer 2001;1:149-156.
50. Madalinska JB, van Beurden M, Bleiker EM, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006;24:3576-3582. (Pubitemid 46630529)
51. Wren B. Hormonal therapy and genital tract cancer. Curr Opin Obstet Gynecol 1996;8:38-41. (Pubitemid 26114742)
52. Anderson GL, Limacher M, Assaf AR, et al. Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmeno-pausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712. (Pubitemid 38489892)
53. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427. (Pubitemid 36999703)
54. Armstrong K, Schwartz J, Randall T, et al. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 2004;22:1045-1054. (Pubitemid 41095037)
55. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005;23:7804-7810. (Pubitemid 46657377)
56. Eisen A, Lubinski J, Gronwald J, et al. Hereditary Breast Cancer Clinical Study Group Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008;100:1361-1367.
57. Gabriel CA, Tigges-Cardwell J, Stopfer J, Erlichman J, Nathanson K, Domchek SM. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Fam Cancer 2009;1:23-28.
58. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancerVis it safe?), a randomized comparison: trial stopped. Lancet 2004;363:453-455. (Pubitemid 38210063)